{
    "clinical_study": {
        "@rank": "72124", 
        "arm_group": [
            {
                "arm_group_label": "enteral nutrition+azathioprine", 
                "arm_group_type": "Experimental", 
                "description": "Patients is fasting and receive enteral nutrition and azathioprine treatment."
            }, 
            {
                "arm_group_label": "azathioprine", 
                "arm_group_type": "Experimental", 
                "description": "Patients have regular diet and receive only azathioprine treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "Crohn's disease(CD) is a agnogenic disease which has a lifelong relapse tendency even after\n      surgery treatment.So maintain remission medications were routinely given to patients after\n      surgery.But maintain remission medications,as azathioprine,6-MP, ciclosporin,tripterygium\n      glycosides, had a onset time.The therapeutic effect may appear 3 months~6months after taken\n      medicine.There is a treatment blank period between surgery and onset time of maintain\n      remission medications.Enteral nutrition has been used in the induction remission and\n      maintain remission for CD.May be it can fill the treatment blank period."
        }, 
        "brief_title": "The Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD)", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Crohn's Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "detailed_description": {
            "textblock": "Crohn's disease(CD) is a agnogenic disease which has a lifelong relapse tendency even after\n      surgery treatment.So maintain remission medications were routinely given to patients after\n      surgery.But maintain remission medications,as azathioprine,6-MP, ciclosporin,tripterygium\n      glycosides, had a onset time.The therapeutic effect may appear 3 months~6months after taken\n      medicine.There is a treatment blank period between surgery and onset time of maintain\n      remission medications.Enteral nutrition has been used in the induction remission and\n      maintain remission for CD.May be it can fill the treatment blank period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects should have a definitive diagnosis of Crohn's disease, based on WHO criteria\n\n          -  Subjects having curative resection/ileocolonic anastomosis\uff0cpathologically diagnosed\n             as Crohn's disease\n\n          -  Lesions located in ileum or ileocecal region\n\n          -  Males and females \u2265 18 years old, including women who are not pregnant or lactating\n             at the time of enrollment.\n\n          -  Body weight between 40 and 100 kg, inclusive.\n\n          -  Subjects should have a CDAI score <150 at week 0\n\n          -  Able to swallow tablets\n\n          -  Are capable of providing written informed consent and obtained at the time of\n             enrollment\n\n          -  Willing to adhere to the study visit schedule and other protocol requirements.\n\n        Exclusion Criteria:\n\n          -  Bacterial,viral or other microbial infection(including HIV)\n\n          -  any of the following medications taken within 12 weeks before surgery: cyclosporine,\n             tacrolimus, sirolimus, mycophenolate mofetil, or other investigational drugs\n\n          -  any of ongoing therapy for Crohn's disease with: 5-ASA compounds, steroids, immune\n             modifiers, systemic antibiotics, and tube feeding\n\n          -  Needing orally administered corticosteroids for the treatment of other diseases.\n             Inhaled or dermatologic preparations are acceptable.\n\n          -  Previous or current use of infliximab.\n\n          -  current use of prescription doses or chronic/frequent use of NSAIDs\n\n          -  Treatment with narcotic pain medications. (Anti-diarrheal agents such as loperamide\n             and diphenoxylate are permitted, providing that the dose is not increased during the\n             study period.)\n\n          -  History of pancreatitis, except for subjects with a known but removed cause(such as\n             gallstone pancreatitis)\n\n          -  WBC <3.0 x 109/L, hemoglobin <80 g/L, Platelets<50,000/mm3 at the time of enrollment\n             (or within the previous 6 months, if known)\n\n          -  History of abnormal liver function tests, including AST or ALT >1.5 times upper limit\n             of normal, alkaline phosphatase >2 times upper limit of normal, total bilirubin >2.5\n             mg/dL at screening (or within the previous 6 months, if known)\n\n          -  With short bowel syndrome (defined as requiring oral or parenteral supplemental or\n             total nutrition to maintain stable body weight, or more than 100 cm of small bowel\n             resected)\n\n          -  History of malignancy\n\n          -  Women who are pregnant or lactating at the time of enrollment, or who intend to be\n             during the study period.\n\n          -  Participation in other clinical trial within the past 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01823042", 
            "org_study_id": "CDS-2"
        }, 
        "intervention": [
            {
                "arm_group_label": "enteral nutrition+azathioprine", 
                "intervention_name": "azathioprine+enteral nutrition", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "azathioprine", 
                "intervention_name": "Azathioprine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Azathioprine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Crohn's Disease", 
            "maintain remission", 
            "postoperative recurrence", 
            "surgery", 
            "living quality"
        ], 
        "lastchanged_date": "March 28, 2013", 
        "location": {
            "contact": {
                "email": "dr_zhuweiming@126.com", 
                "last_name": "wei ming zhu, PhD,MD", 
                "phone": "+86-25-80860137"
            }, 
            "facility": {
                "address": {
                    "city": "Nanjing", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "210000"
                }, 
                "name": "General Surgery Institute,Jinling Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Controlled, Open-label Study to Assess the the Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD).", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The change of patients'CDAI.", 
                "safety_issue": "No", 
                "time_frame": "at 0 week, the 4 weeks, the 8 weeks, the 12weeks"
            }, 
            {
                "measure": "patients' endoscopic score(Rutgeerts score).", 
                "safety_issue": "No", 
                "time_frame": "at the 12weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01823042"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jinling Hospital, China", 
            "investigator_full_name": "Zhu Weiming", 
            "investigator_title": "vice director of General surgery institute", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "The change of haematological inflammation marker(CRP,ESR)", 
                "safety_issue": "No", 
                "time_frame": "at 0 week, the 4 weeks, the 8 weeks, the 12weeks"
            }, 
            {
                "measure": "The change of patients'IBDQ.", 
                "safety_issue": "No", 
                "time_frame": "at 2 week, the 6 weeks, the 12 weeks"
            }, 
            {
                "measure": "The change of blood routine examination and blood biochemistry.", 
                "safety_issue": "No", 
                "time_frame": "at 0 week,4 weeks,8 weeks,12 weeks"
            }
        ], 
        "source": "Jinling Hospital, China", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jinling Hospital, China", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}